Identifying the molecular cascade that leads to plasticity should define your investment. Most investors never look at it. They read MADRS scores and phase two data. That is a problem. Here is why.
Trap One: Bias Agonism. A compound shows efficacy in phase two. Investors assume the mechanism being marketed is the one doing the work. Often it is not. A biased agonist can look clean on paper, reduced Gq, preserved plasticity, but if the Emax is too low, you have actually killed the effect. The MADRS improvement is real. You just do not know if it is coming from the plasticity pathway you thought you were targeting, or from something else entirely.
Trap Two: The Unknown Plasticity Pathway. Two compounds show similar MADRS improvements over an eight week trial. Investors assume they are mechanistically equivalent. But one might be driving plasticity through Gq activation. The other might be riding beta arrestin signalling, which desensitizes the receptor. Same clinical outcome in that window. Extend the trial to six months and one holds, the other fades. You will not see that divergence in the published data. That is the trap.
“Understanding plasticity pathways is not academic rigor. It is the difference between backing a durable effect and backing a mirage.”
Trap Three: Acute Occupancy Versus Sustained Effect. LSD binds to the 5-HT2A receptor longer than psilocybin. Investors see that data and assume LSD should produce bigger plasticity effects. Clinically, it does not scale that way. Occupancy time does not predict sustained pathway activation. A compound with longer binding might desensitize faster through beta arrestin. A compound with shorter binding might maintain cleaner signalling. The endpoint, MADRS improvement, masks this entirely. You are optimizing for the wrong variable and you do not know it.
Clinical endpoints tell you what happened. Molecular cascades tell you why it happened and whether it will last. Most investors read one and ignore the other. Understanding plasticity pathways is not academic rigor. It is the difference between backing a durable effect and backing a mirage.